Valuation: Immuneering Corporation

Market Cap 260M 233M 214M 194M 363M 24.7B 370M 2.56B 1.03B 12.99B 976M 955M 40.97B P/E 2026 *
-3.59x
P/E 2027 * -3.2x
Enterprise Value 260M 233M 214M 194M 363M 24.7B 370M 2.56B 1.03B 12.99B 976M 955M 40.97B EV / Sales 2026 *
-
EV / Sales 2027 * 13.3x
Free-Float
86.17%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day-6.84%
1 week+0.40%
Current month-8.55%
1 month-8.55%
3 months-11.47%
6 months-28.53%
Current year-43.09%
1 week 3.65
Extreme 3.65
4.16
1 month 3.38
Extreme 3.38
4.17
Current year 3.38
Extreme 3.38
8.48
1 year 3.38
Extreme 3.38
8.48
3 years 1
Extreme 1
10.08
5 years 1
Extreme 1
31.88
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 31/01/2008
Director of Finance/CFO 62 15/07/2026
Chief Tech/Sci/R&D Officer - 31/07/2023
Director TitleAgeSince
Chairman 81 31/12/2007
Director/Board Member 44 31/01/2008
Director/Board Member 72 26/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Other

Chief Financial Officer

225,000 0.3478%
16/07/26 Free

Chief Financial Officer

650,000 1.0047%
13/03/26 Free

Head of Human Resources

3,628 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-6.84%+0.40%-41.58%-37.16% 260M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.61%+4.88%+43.66%+144.18% 39.29B
Weighted average by Cap. +0.00%+3.75%+49.78%+162.51%

Financials

2026 *2027 *
Net sales - 19.5M 17.46M 16.06M 14.56M 27.21M 1.85B 27.72M 192M 76.9M 974M 73.18M 71.63M 3.07B
Net income -74.1M -66.37M -61.05M -55.31M -103M -7.04B -105M -728M -292M -3.7B -278M -272M -11.67B -85.92M -76.95M -70.78M -64.13M -120M -8.16B -122M -844M -339M -4.29B -322M -316M -13.53B
Net Debt - -
Projected Income Statement - Annual - Immuneering Corporation
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
57
Date Price Change Volume
30/10/26 US$3.745 -6.84% 1,138,565
29/10/26 US$4.020 +0.75% 777,032
28/10/26 US$3.990 +4.18% 1,442,688
27/10/26 US$3.830 +3.23% 700,080
26/10/26 US$3.710 -0.54% 579,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immuneering Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.020USD
Average target price
17.00USD
Spread / Average Target
+322.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immuneering Corporation
  1. Stock Market
  2. Stocks
  3. IMRX Stock